FIELD: biotechnology; medicine.
SUBSTANCE: invention relates to biotechnology, molecular immunology and medicine. What is presented is a chimeric immunotoxin based on the non-structural glycoprotein NSP4 of human rotavirus, which exhibits an increased cytotoxic effect on the tumour-associated MUC1 of cancer cells. Immunotoxin contains a single-chain antibody binding tumour-associated MUC1, and a peptide consisting of amino acids 112-174 of non-structural glycoprotein NSP4 of human rotavirus, connected by a peptide linker. Chimeric immunotoxin initiates cell cycle arrest and cancer cell apoptosis, which provides cytotoxic activity in lower concentrations.
EFFECT: invention can find further application in developing monitoring and therapeutic approaches in treating patients with malignant neoplasms.
1 cl, 5 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES BINDING TUMOR-ASSOCIATED MUC1, AND METHODS OF THEIR OBTAINING | 2016 |
|
RU2652901C1 |
| CSF-1R ANTIBODY | 2009 |
|
RU2547586C2 |
| ANTIBODY AGAINS CSF-1R | 2012 |
|
RU2621859C2 |
| ANTIBODIES SPECIFIC TO TUMOUR AND USE THEREOF | 2011 |
|
RU2595403C2 |
| RECOMBINANT IMMUNOTOXIN AIMED AT MESOTHELIN | 2012 |
|
RU2600067C2 |
| CONSTRUCTION OF OBLIGATE VECTOR BASED ON ONCOLYTIC HERPES SIMPLEX VIRUSES (oHSV) AND CONSTRUCT FOR CANCER THERAPY | 2016 |
|
RU2831084C2 |
| EXOTOXIN A PSEUDOMONAS WITH LESS IMMUNOGENIC T-AND/OR B-CELL EPITHOPES | 2012 |
|
RU2627216C2 |
| HIGH-AFFINITY ANTI-CD3 ANTIBODIES AND METHODS FOR PRODUCTION AND USE THEREOF | 2020 |
|
RU2831840C2 |
| MONOMOLECULAR CHEMERIC T-CELLULAR RECEPTOR TO CANCER-EMBRYONIC ANTIGEN | 2015 |
|
RU2650858C2 |
| MONOMOLECULAR CHIMERIC T-CELLULAR RECEPTOR TO CANCER-EMBRYONIC ANTIGEN | 2015 |
|
RU2652955C1 |
